BRCA1 and carcinoma: It was reported that approximately 45% of patients with platinum-resistant recurrent ovarian cancer have secondary mutations restoring BRCA1/2; this rate is significantly higher than that in platinum-sensitive recurrent cancer, and the secondary somatic mutations that restore BRCA1/2 in carcinomas with germline BRCA1/2 mutations predict resistance to platinum chemotherapy or PARPi [31].